Taken together, these direct effects of GLP-1 agonist on hepatocytes, Kupffer cells, and hepatic stellate cells, as well as the improvement in glucose homeostasis, could have contributed to the prevention of NASH progression and hepatocarcinogenesis in the current study. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.